Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.

ABSTRACT:

Objective

The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea.

Research design and methods

The study randomized 231 patients with poorly controlled (HbA_1c >7.5%, 58 mmol/mol) T2DM on a sulfonylurea plus metformin to receive 1) pioglitazone plus weekly exenatide (combination therapy) or 2) basal plus prandial insulin (insulin therapy) to maintain HbA_1c <7.0% (53 mmol/mol).

Results

After a mean follow-up of 12 months, combination therapy caused a robust decrease in HbA_1c from 10.0 ± 0.6% (86 ± 5.2 mmol/mol) at baseline to 6.1 ± 0

SUBMITTER: Abdul-Ghani M 

PROVIDER: S-EPMC5864032 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature